Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CVM

Cel-Sci Corp

Sep 15 • 03:04PM ET

9.97

-0.28 -2.73 %

Healthcare • Biotechnology • USA • AMEX

Peers: ARWR AGEN BCRX DNA KPTI AFMD IMUX ABEO PSTV CLSD

Index	-	P/E	-	EPS (ttm)	-9.82	Insider Own	8.11%	Shs Outstand	7.99M	Perf Week	-3.67%
Market Cap	79.66M	Forward P/E	-	EPS next Y	-2.84	Insider Trans	5.21%	Shs Float	7.35M	Perf Month	22.49%
Enterprise Value	87.83M	PEG	-	EPS next Q	-	Inst Own	7.92%	Short Float	10.43%	Perf Quarter	343.12%
Income	-25.42M	P/S	-	EPS this Y	64.44%	Inst Trans	88.30%	Short Ratio	0.92	Perf Half Y	9.32%
Sales	0.00M	P/B	7.55	EPS next Y	47.79%	ROA	-114.49%	Short Interest	0.77M	Perf YTD	-16.89%
Book/sh	1.32	P/C	44.50	EPS next 5Y	60.82%	ROE	-328.04%	52W High	39.30 -74.63%	Perf Year	-71.84%
Cash/sh	0.22	P/FCF	-	EPS past 3/5Y	17.72% 6.84%	ROIC	-174.17%	52W Low	1.98 403.55%	Perf 3Y	-92.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.65% 11.79%	Perf 5Y	-97.64%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	42.29%	Oper. Margin	-	ATR (14)	1.23	Perf 10Y	-97.54%
Dividend Ex-Date	-	Quick Ratio	0.37	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.05	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.47	EPS Q/Q	64.18%	SMA20	-3.25%	Beta	0.55	Target Price	60.00
Payout	-	Debt/Eq	1.42	Sales Q/Q	-	SMA50	25.92%	Rel Volume	0.14	Prev Close	10.25
Employees	-	LT Debt/Eq	1.08	Earnings	Aug 14 BMO	SMA200	7.68%	Avg Volume	833.75K	Price	9.97
IPO	Dec 08, 1983	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	102,149	Change	-2.73%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-20	Initiated	H.C. Wainwright	Buy	$18
Mar-02-15	Initiated	Dawson James	Buy	$3

Aug-14-25 10:45AM	CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results (Business Wire)
09:37AM	Cel-Sci: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Aug-13-25 09:15AM	CEL-SCIs Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline (Business Wire) +9.44%
Jul-14-25 04:05PM	CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules (Business Wire)
Jul-11-25 12:16PM	CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules (Business Wire) -7.59%
09:15AM	Loading…
09:15AM	CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer (Business Wire)
Jun-18-25 09:00AM	FDAs Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCIs Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients (Business Wire)
May-23-25 04:05PM	CEL-SCI Announces Closing of Public Offering (Business Wire)
May-21-25 08:14PM	CEL-SCI Announces Pricing of Public Offering (Business Wire) -11.74% -45.45%
04:05PM	CEL-SCI Announces Proposed Public Offering (Business Wire)
08:00AM	CEL-SCIs Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia (Business Wire)
May-19-25 02:40PM	CEL-SCI Announces Combination of Common Stock (Business Wire) -8.61%
May-15-25 09:00AM	CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results (Business Wire)
May-14-25 07:30PM	Cel-Sci: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -6.84%
Apr-23-25 08:30AM	CEL-SCI to File for Regulatory Approval of Multikine in Saudi ArabiaPursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market (Business Wire) +5.20%
10:15AM	Loading…
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire) -21.86%
Apr-08-25 09:51AM	New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCIs Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses (Business Wire) -8.29%
Mar-24-25 09:00AM	CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients (Business Wire)
Mar-18-25 04:05PM	CEL-SCI Announces Closing of $2.5 Million Offering (Business Wire) +5.24%
Mar-17-25 03:24PM	CEL-SCI Announces Pricing of $2.5 Million Offering (Business Wire) -6.55%
08:00AM	CEL-SCIs Head and Neck Cancer Registration Study Protocol Clears FDA Reviewin Talks with Potential Partners Interested in Commercialization of Multikine (Business Wire)
Mar-14-25 08:30AM	Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCIs Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression (Business Wire)
Feb-20-25 08:00AM	CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial (Business Wire) -17.50%
Feb-18-25 08:30AM	CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks (Business Wire) +6.91%
Feb-14-25 04:24PM	Cel-Sci: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Jan-14-25 09:00AM	CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer (Business Wire)
Dec-31-24 04:05PM	CEL-SCI Announces Closing of $5 Million Offering (Business Wire)
Dec-29-24 08:41PM	CEL-SCI Announces Pricing of $5 Million Public Offering (Business Wire)
Dec-27-24 05:05PM	CEL-SCI Announces Proposed Public Offering of Common Stock (Business Wire) -14.87% -32.26%
Dec-12-24 09:15AM	CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study (Business Wire) +10.86%
08:15AM	Loading…
Nov-07-24 08:15AM	U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025 (Business Wire) -7.92%
Oct-22-24 09:15AM	FDAs Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCIs Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients (Business Wire)
Oct-01-24 06:00AM	CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer (Business Wire)
Sep-16-24 07:30AM	CEL-SCIs Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation (Business Wire) -10.16%
Sep-10-24 09:32AM	CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress (Business Wire)
Sep-04-24 09:00AM	The UKs Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance (Business Wire)
Aug-15-24 08:00AM	CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results (Business Wire)
05:09AM	Cel-Sci: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Jul-29-24 04:05PM	CEL-SCI Announces Closing of $10.8 Million Offering (Business Wire) -5.34%
Jul-26-24 11:52AM	CEL-SCI Announces Pricing of $10.8 Million Offering (Business Wire) +8.26%
08:23AM	CEL-SCIs Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results (Business Wire)
Jul-08-24 09:15AM	CEL-SCI Appoints Robert Watson as Chairperson of the Board (Business Wire)
Jun-18-24 08:00AM	CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population (Business Wire) -11.20%
Jun-06-24 07:00AM	Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor (Business Wire)
May-16-24 09:08AM	Cel-Sci: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
09:00AM	CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results (Business Wire)
May-08-24 04:02PM	Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine (MT Newswires) -16.77% +8.63%
09:00AM	CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer (Business Wire)
Apr-23-24 09:00AM	CEL-SCI Appoints Mario Gobbo to Its Board of Directors (Business Wire)
Mar-19-24 09:00AM	CEL-SCIs LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology (Business Wire)
Mar-06-24 08:45AM	CEL-SCI Corporation Issues Letter to Shareholders (Business Wire) +8.07%
Feb-15-24 08:00AM	CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results (Business Wire)
Feb-14-24 05:11PM	Cel-Sci: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Feb-13-24 12:00PM	CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock (Business Wire)
Feb-09-24 08:30AM	CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock (Business Wire) -13.68%
Feb-06-24 09:00AM	CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug (Business Wire) +5.48%
Jan-31-24 09:00AM	European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® (Business Wire)
Dec-22-23 08:00AM	CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments (Business Wire)
Dec-04-23 08:30AM	UKS National Institute for Health and Care Excellence (NICE) Selects CEL-SCIs Multikine as Potential New Standard of Care for Head & Neck Cancer (Business Wire) +35.27%
Nov-20-23 04:15PM	CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock (Business Wire) +11.01%
Nov-16-23 08:30AM	CEL-SCI Announces Pricing of $5 Million Offering of Common Stock (Business Wire) -22.57%
Nov-09-23 08:52AM	12 Best Day Trading Stocks To Buy (Insider Monkey) -6.27%
Oct-30-23 09:20AM	CEL-SCI Issues Letter to Shareholders (Business Wire) +8.26%
Oct-24-23 08:00AM	CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals (Business Wire)
Oct-23-23 09:15AM	5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCIs Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023 (Business Wire) +41.12%
Oct-19-23 08:00AM	CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production (Business Wire)
Oct-09-23 07:50AM	CVM: Regulatory Journey Accelerating (Zacks) -5.04%
Oct-05-23 08:45AM	CEL-SCI Files Request With the UKs MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer (Business Wire) -6.03%
Sep-26-23 09:00AM	CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer (Business Wire)
Aug-11-23 08:07AM	Cel-Sci: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -12.68%
08:00AM	CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results (Business Wire)
Jul-31-23 05:49AM	CVM: Model Revisions (Zacks)
Jul-20-23 11:36AM	CEL-SCI Announces Closing of Public Offering (Business Wire) -8.80%
Jul-17-23 09:23PM	CEL-SCI Announces Pricing of Public Offering (Business Wire) +11.72% -23.43%
04:05PM	CEL-SCI Announces Proposed Public Offering of Common Stock (Business Wire)
Jul-14-23 09:15AM	CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikines Approval for Head & Neck Cancer (Business Wire) +9.40%
Jul-11-23 08:45AM	CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikines Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer (Business Wire)
Jun-22-23 10:19AM	CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck CancerNew Patent to Be Filed (Business Wire)
May-16-23 09:17AM	CVM: Health Canada Conditional Approval (Zacks Small Cap Research)
May-15-23 02:18PM	Why CEL-SCI Shares Are Shooting Higher Today (Benzinga) +8.33%
09:00AM	Histopathology and Tumor Biomarker Analysis Confirm CEL-SCIs Multikine Significantly Prolonged Overall Survival in Head & Neck CancerPhase 3 Data Presented at ESTRO 2023 (Business Wire)
May-12-23 04:35PM	Cel-Sci: Fiscal Q2 Earnings Snapshot (AP Finance) -11.44%
04:30PM	CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results (Business Wire)
Apr-27-23 09:12PM	CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock (Business Wire)
Apr-19-23 09:00AM	CEL-SCI to Pursue Canadas Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer (Business Wire) +15.04%
Mar-08-23 09:00AM	CEL-SCIs Multikine Phase 3 Cancer Study Shows 43% Survival Extension (Business Wire) -5.19%
Mar-03-23 09:00AM	CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology (Business Wire) +26.50%
Feb-27-23 05:26AM	CVM: BLA Filing Still on the Horizon (Zacks Small Cap Research)
Feb-15-23 09:00AM	CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results (Business Wire)
Jan-03-23 11:57AM	CVM: A New Year Ahead (Zacks Small Cap Research) +5.11%
Dec-28-22 09:00AM	CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments (Business Wire) +9.18%
Nov-22-22 12:21PM	10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients (Benzinga)
09:00AM	CEL-SCI Corporation Issues Letter to Shareholders (Business Wire)
Oct-17-22 08:50AM	CEL-SCIS Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment (Business Wire)
Sep-12-22 09:00AM	CEL-SCIS Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer (Business Wire)
Sep-07-22 08:45AM	CEL-SCI Corporation Issues Letter to Shareholders (Business Wire) +5.84%
Aug-24-22 05:45AM	CVM: ClinicalTrials Submission (Zacks Small Cap Research)
Aug-19-22 08:45AM	CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov (Business Wire)
Aug-15-22 09:00AM	CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results (Business Wire) +25.42%
Aug-08-22 08:45AM	CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors (Business Wire)

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Watson Robert Eugene	Director	Jul 25 '25	Buy	6.85	2,919	19,995	3,733	Jul 29 07:56 AM
KERSTEN GEERT R	Chief Executive Officer	Jul 25 '25	Buy	6.85	29,197	199,999	72,835	Jul 28 09:36 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVM

Cel-Sci Corp

Upgrade your FINVIZ experience